Abstract. The selective induction of apoptosis is a promising strategy for cancer therapy. The antitumor effects of oridonin have been reported in several types of malignant tumors. However, the effects of oridonin on MHCC97-H cells, a highly metastatic human hepatocellular carcinoma cell line, have not been reported. The present study aimed to determine the effect of oridonin on the apoptosis of MHCC97-H cells and to identify the underlying molecular mechanisms that are involved. Compared with the untreated control cells, oridonin significantly decreased (P<0.05) cell proliferation in a concentration- and time-dependent manner. Oridonin at concentrations of 12.5, 25, 50 and 100 µM resulted in increased apoptotic Annexin V-positive and propidium iodide-negative cells by 9.5, 15.6, 22.2 and 31.7%, respectively, compared with the control groups (P<0.05). The mitochondrial membrane potential was significantly decreased by 6.0, 12.9, 18.9 and 27.1% in the MHCC97-H cells that were treated with oridonin at concentrations of 12.5, 25, 50 and 100 µM, respectively, for 24 h compared with the control groups (P<0.05). Oridonin increased the activity of caspase-3 and the expression of cleaved caspase-9 and cytochrome c in the cytoplasm and decreased the Bcl-2:Bax ratio in a concentration-dependent manner. The data indicate that oridonin inhibited the proliferation of the MHCC97-H cells by inducing apoptosis via a mitochondrial pathway. This mitochondrial pathway of apoptosis involved a reduction in the mitochondrial membrane potential and the subsequent release of cytochrome c and activation of caspase-3 and -9.

Introduction

Hepatocellular carcinoma (HCC) is one of the most frequently occurring cancers in the world, resulting in approximately one million deaths every year (1). The majority of liver cancers are diagnosed at later stages due to the absence of symptoms in patients and an incorrect liver disease diagnosis. Surgical options for patients with HCC include a resection of the primary tumor and liver transplantation (2). As HCC is typically diagnosed at an advanced stage, a resection of the primary tumor is typically not an option and >80% of HCC patients have recurrent disease within two years following the surgery. Recurrence and metastasis are the two main causes of patient mortality. Recent advances in our understanding of the biology and signaling pathways of HCC have led to apoptosis induction being considered as a new treatment strategy for HCC (3).

Studies have focused on Rabdosia rubescens, which is used as a herbal medicine, due to its antitumor effects and lack of serious side-effects (4,5). Oridonin, a diterpenoid that is isolated from R. rubescens, has shown antitumor effects in several malignant tumors, including breast and cervical carcinoma and lymphoma (6,7). Oridonin has been demonstrated to induce apoptosis in HepG2 HCC cells, which have a moderate metastatic potential (8,9). However, the effect of oridonin on human HCC cell lines with a high metastatic potential has not been determined. Therefore, the present study investigated the effect of oridonin on the apoptosis of the highly metastatic MHCC97-H HCC cell line and the underlying molecular mechanism involved.

Materials and methods

Reagents. High glucose Dulbecco's modified Eagle's medium (DMEM) and fetal calf serum (FCS) were purchased from HyClone (Beijing, China). The Annexin V Alexa Fluor 488/propidium iodide (PI) Apoptosis, MTS/PMS Cell Proliferation Assay, Active Caspase-3 Staining and Cytoplasmic and Mitochondrial Protein Extraction kits were purchased from Invitrogen (Carlsbad, CA, USA), Promega (Madison, WI, USA), Biovision (Milpitas, CA, USA) and Sangon Biotech Co. Ltd (Shanghai, China), respectively. The Z-LEHD-FMK caspase-9 inhibitor, rhodamine-123 and 3,3'-diaminobenzidine tetrahydrochloride (DAB) were purchased from R&D Systems (Minneapolis, MN, USA), Sigma Chemical Co. (St. Louis, MO, USA) and Dako (Glostrup, Denmark), respectively. Cytochrome c, Bcl-2 and Bax monoclonal antibodies and horseradish peroxidase (HRP)-conjugated secondary anti-
bodies (goat-anti-rabbit and goat-anti-mouse) were purchased from Epitomics (Burlingame, CA, USA). Caspase-9 and glyceraldehyde 3-phosphate dehydrogenase monoclonal antibodies were purchased from Cell Signaling (Danvers, MA, USA). Oridonin (Lot, 111721-200501; 97% purity) was obtained from the Beijing Institute of Biological Products (Beijing, China). Oridonin was prepared in dimethyl sulfoxide (DMSO).

Cell culture. The human MHCC97-H HCC cell line was obtained from the Hepatic Carcinoma Institute, Fudan University (Shanghai, China). The MHCC97-H cells were cultured in DMEM supplemented with 10% FCS at 37°C in a humidified atmosphere, with 5% CO₂. All the experiments were performed with cells in the logarithmic growth phase. The DMSO concentration in the cell cultures (≤0.5%) did not affect the cell viability.

MTS/PMS assay for cell proliferation. The MHCC97-H cells were seeded into 96-well plates at a density of 1x10⁴ cells/ml. The cells were treated with oridonin at concentrations of 6.25, 12.5, 25, 50 and 100 µM for 24, 48 and 72 h. The untreated cells served as the controls. Proliferation was determined using the MTS/PMS Cell Proliferation Assay kit, according to the manufacturer's instructions. MTS/PMS (10 µl) was added to each well and incubated at 37°C for 2 h. The absorbance was measured at 490 nm on a multi-well plate reader.

Cell morphology. The MHCC97-H cells were treated with oridonin at concentrations of 6.25, 12.5, 25, 50 and 100 µM for 24, 48 and 72 h, respectively. The percentage of viable cells was 95.5, 82.8, 68.3, 51.6 and 22.4% for the cells that were treated with 6.25, 12.5, 25, 50 and 100 µM oridonin for 24 h, respectively. The percentage of viable cells was 96.2, 88.1, 77.5, 68.5 and 58.6% for the cells that were treated with 6.25, 12.5, 25, 50 and 100 µM oridonin for 48 h, respectively. The percentage of viable cells was 58.6, 88.1, 77.5, 68.5 and 53.7% for the cells that were treated with 6.25, 12.5, 25, 50 and 100 µM oridonin for 72 h, respectively. The difference between the test group and the control group was significant (P<0.05). The data indicated that the growth inhibitory effect of oridonin on the MHCC97-H cells was dependent on the concentration and the duration of the treatment. The 6.25 µM concentration of oridonin was found to be most effective in inhibiting cell proliferation.
oridonin was not included in the further experiments due to the weak anti-proliferative effect.

**Effect of oridonin on the apoptosis of MHCC97-H cells.** The percentage of Annexin V-positive and PI-negative MHCC97-H cells that were treated with oridonin is shown in Fig. 2. The percentage of the apoptotic cells was significantly higher (P<0.05) for the oridonin-treated cells than for the untreated control cells. Furthermore, oridonin increased the percentage of apoptotic cells in a concentration-dependent manner. The percentage of apoptotic cells (Annexin V-positive and PI-negative) was 9.5, 15.6, 22.2 and 31.7% in the MHCC97-H cells that were treated with 12.5, 25, 50 and 100 µM oridonin for 24 h. Addition of the caspase-9 inhibitor, Z-LEHD-FMK, significantly lowered (P<0.05) the percentage of apoptotic cells that were induced by the 100-µM concentration of oridonin (11.7 vs. 31.7%).

**Effect of oridonin on the mitochondrial membrane potential of MHCC97-H cells.** The mitochondrial membrane potential was decreased by oridonin in a concentration-dependent manner. The mitochondrial membrane potential was significantly decreased (P<0.05) by 12.9, 18.9 and 27.1% in the MHCC97-H cells that were treated with 25, 50 and 100 µM oridonin, respectively (Fig. 3). By contrast, the decrease in the mitochondrial membrane potential (6.0%) was not significantly different between the 12.5 µM oridonin-treated cells and the control cells. The ratio of the mitochondrial membrane potential prior to and following the oridonin treatment is shown in Fig. 3.

**Effect of oridonin on caspase-3 activity of MHCC97-H cells.** Oridonin increased caspase-3 activity in the MHCC97-H cells (Fig. 4). Caspase-3 activity was significantly increased (P<0.05) by 13.2, 21.6, 29.7 and 43.6% in the cells that were treated with 12.5, 25, 50 and 100 µM oridonin for 24 h. Caspase-3 activity was positively correlated with the oridonin concentration (r²=0.9538).

**Effect of oridonin on the expression of apoptotic proteins in MHCC97-H cells.** The effect of oridonin at concentrations of 12.5, 25, 50 and 100 µM on the expression of the apoptosis-related proteins, including Bcl-2, Bax, cytochrome c and caspase-9, is shown in Fig. 5. Bcl-2 expression was significantly decreased (P<0.05) and Bax expression was significantly increased (P<0.05) by all the concentrations of oridonin. The expression of cleaved caspase-9 and cytoplasmic cytochrome c...
was significantly increased (P<0.05) by oridonin at concentrations of 25, 50 and 100 µM. Oridonin at a concentration of 100 µM significantly decreased (P<0.05) the expression of mitochondrial cytochrome c.

**Effect of oridonin on the morphology of MHCC97-H cells.**
The untreated control MHCC97-H cells had an epithelioid morphology with a large, round or oval nucleus and abundant cytoplasm (Fig. 6; left panel). The morphological alterations that are associated with cells undergoing apoptosis, including cell shrinkage, nuclear fragmentation and chromatin condensation, were observed in the cells that were treated with 50 µM oridonin for 24 h (Fig. 6; right panel). Necrosis was evident in the cells that were treated with 50 µM oridonin for ≥48 h.

**Discussion**

The present study investigated the apoptotic potential of oridonin in MHCC97-H cells, a human hepatoma cell line with a high metastatic capacity (11,12). Oridonin decreased the number of viable cells and increased the percentage of apoptotic cells. Therefore, oridonin inhibited the proliferation of the MHCC97-H cells by inducing apoptosis. The IC\textsubscript{50} of oridonin, which was calculated using the Bliss method (13), was 142.2, 80.8 and 44.6 µM for the 24-, 48- and 72-h treatments, respectively. These data indicate that the growth inhibitory effect of oridonin is concentration- and time-dependent. Zhang et al (14) reported that the MHCC97-H cell line has a higher invasive and metastatic potential than HepG2 and SMMC7721 HCC cell lines. Previously, we reported that the 24 h IC\textsubscript{50} of oridonin in HepG2 cells was 27.6 µM (8). These findings are in agreement with those of Huang et al (9). Taken together, these findings indicate that the effective inhibitory concentration of oridonin is higher in MHCC97-H cells than in HepG2 cells and is likely to be the result of the various metastatic potentials of these cell lines.

The present study indicates that a mitochondrial pathway is involved in oridonin-induced apoptosis in MHCC97-H cells. Cell apoptosis or programmed cell death is significant in the maintenance of the intrinsic stability of multicellular organisms (15). Previous studies have indicated that interactions between multiple genes and their composite regulation were involved in the induction of apoptosis (15-19). It is now known that membrane receptor and mitochondrial pathways are the main regulators of apoptosis. Mitochondrial pathways play
significant roles in the regulation of apoptosis by inducing the mitochondrial permeability transition pore (20). Pro-apoptotic factors induce mitochondrial permeability transition pore formation, which leads to the loss of membrane potential and cytochrome c release into the cytoplasm. Cytochrome c binds caspase-9 and Apaf-1 to form a complex that activates other caspase family members, including caspase-3 and caspase-6, to induce apoptosis (21). The present study identified that oridonin decreased the mitochondrial membrane potential and mitochondrial cytochrome c expression and increased cytoplasmic cytochrome c expression in the MHCC97-H cells. Furthermore, the activity of caspase-9 and caspase-3 was increased by oridonin, while the caspase-9 inhibitor, Z-LEHD-FMK, decreased oridonin-induced apoptosis. Taken together, these findings indicate that a mitochondrial pathway is involved in oridonin-induced apoptosis in MHCC97-H cells.

Members of the Bcl-2 family, including Bcl-2 and Bax, play a significant role in the mitochondrial pathway of apoptosis (22,23). Bax is a pro-apoptotic factor that is located in the mitochondrial matrix. Bcl-2 is an anti-apoptotic factor that is located in the outer layer of the mitochondrial membrane. Bax and Bcl-2 regulate apoptosis by controlling the activity of proteases and nucleases. Bax promotes apoptosis in response to certain mitochondrial stimuli by inducing the opening of the mitochondrial permeability transition pore to release cytochrome c. Bcl-2 antagonizes the action of Bax by preventing the opening of the mitochondrial permeability transition pore (23). The present study demonstrated that oridonin decreased Bcl-2 expression and increased Bax expression in a concentration-dependent manner, resulting in a decreased Bcl-2/Bax ratio. The study indicated that oridonin induced apoptosis in the MHCC97-H cells. Therefore, these proteins may be involved in oridonin-induced apoptosis.

In summary, oridonin inhibited the proliferation of the MHCC97-H cells by promoting apoptosis. Oridonin induced apoptosis via a mitochondrial pathway that involved a reduction in the mitochondrial membrane potential to promote the release of cytochrome c and the activation of caspase-3 and -9. Further investigation of the molecular mechanisms by which oridonin induces apoptosis is required.

References

1. Barazani Y, Hiatti JR, Tong MJ and Busuttil RW: Chronic viral hepatitis and hepatocellular carcinoma. World J Surg 31: 1243-1248, 2007.
2. Fancellu A, Rosman AS, Sanna V, Nigri GR, Zorcolo L, Pisano M and Melis M: Meta-analysis of trials comparing minimally-invasive and open liver resections for hepatocellular carcinoma. J Surg Res 171: e33-e45, 2011.
3. Bruix J and Sherman M: Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022, 2011.
4. Meade-Tollin LC, Wijeratne EM, Cooper D, et al: Poncidi and oridonin are responsible for the antiangiogenic activity of Rabdosia rubescens, a constituent of the herbal supplement PC SPES. J Nat Prod 67: 2-4, 2004.
5. Saritipour MR, Seeram NP, Heber D, et al: Rabdosia rubescens inhibits breast cancer growth and angiogenesis. Int J Oncol 26: 121-127, 2005.
6. Hsiung TC, Wijeratne EK, Liang JY, Gunatilaka AL and Wu JM: Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by poncidi and oridonin, diterpenoids from the Chinese herb Rabdosia rubescens. Biochem Biophys Res Commun 337: 224-231, 2005.
7. Liu YQ, Mu ZQ, You S, Tashiro S, Onodera S and Ikejima T: Fas/FasL signaling allows extracellular-signal regulated kinase to regulate cytochrome c release in oridonin-induced apoptotic U937 cells. Biol Pharm Bull 29: 1873-1879, 2006.
8. Li B, Zhu M, Wang C, et al: Oridonin upregulates PTEN gene expression and induces apoptosis of HepG2 cells. Herald of Medicine 9: 6, 2008.
9. Huang J, Wu L, Tashiro S, Onodera S and Ikejima T: Reactive oxygen species mediate oridonin-induced HepG2 apoptosis through p53, MAPK, and mitochondrial signaling pathways. J Pharmacol Sci 107: 370-379, 2008.
10. XuZ, ZhouX, LeHe, et al: Comparatively glycoproteomics based on lectins affinity capture of N-linked glycoproteins from human Chang liver cells and MHCC97-H cells. Proteomics 7: 2358-2370, 2007.
11. Sun H and Liu GT: Inhibitory effect of anti-hepatitis drug bicyclofen in vivo on invasion of human hepatocellular carcinoma MHCC97-H cells with high metastasis potential and its relative mechanisms. J Asian Nat Prod Res 11: 576-583, 2009.
12. Tian J, Tang Z and Ye S: Establishment of a human hepatocellular carcinoma (HCC) cell line with high metastatic potential (MHCC97) and its biological characteristics. Zhonghua Zhong Liu Za Zhi 20: 405-407, 1998 (In Chinese).
13. Xiao SH, Xue J and Zhang HB: Further studies on melofquine and praziquantel alone or interaction of both drugs against Schistosoma japonicum in vitro. Parasitol Res 110: 1239-1248, 2011.
14. Zhang Y, Hu MY, Wu WZ, Wang ZJ, Zhou K, Zha XL and Liu KD: The membrane-cytoskeleton organizer ezrin is necessary for hepatocellular carcinoma cell growth and invasiveness. J Cancer Res Clin Oncol 132: 685-697, 2006.
15. Salminen A, Ojala J and Kaarniranta K: Apoptosis and aging: increased resistance to apoptosis enhances the aging process. Cell Mol Life Sci 68: 1021-1031, 2011.
16. Brenner C, Subramaniam K, Pertuisset C and Pervaiz S: Adenine nucleotide translocase family: four isoforms for apoptosis modulation in cancer. Oncogene 30: 883-895, 2011.
17. Dunkle A and He YW: Apoptosis and autophagy in the regulation of T lymphocyte function. Immunol Res 49: 70-86, 2011.
18. Hellwig CT, Passante E and Rehm M: The molecular machinery regulating apoptosis signal transduction and its implication in human physiology and pathophysiologies. Curr Mol Med 11: 31-47, 2011.
19. Sevrioukova IF: Apoptosis-inducing factor: structure, function, and redox regulation. Antioxid Redox Signal 14: 2545-2579, 2011.
20. Sayeed I, Parvez S, Winkler-Stuck K, et al: Patch clamp reveals powerful blockade of the mitochondrial permeability transition pore by the D2-receptor agonist pramipexole. FASEB J 20: 556-558, 2006.
21. Feng R, Han J, Ziegler J, Yang M and Castranova V: Apaf-1 deficiency confers resistance to ultraviolet-induced apoptosis in mouse embryonic fibroblasts by disrupting reactive oxygen species amplification production and mitochondrial pathway. Free Radic Biol Med 52: 889-897, 2012.
22. Ola MS, Nawaz M and Ahsan H: Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem 351: 2011.
23. Reed JC: Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ 13: 1378-1386, 2006.